Who
Robert L. Van Nostrand
Director
Company insider
Files Form 4 as: Director, SELLAS Life Sciences Group; Director, Intra-Cellular Therapies; Director, Yield10 Bioscience; Director, Achillion Pharmaceuticals; Director, Enumeral Biomedical Holdings.
In numbers
- Trades disclosed
- 182
- Buys
- 3
- Sells
- 4
- Bought
- $41K
- Sold
- $5.3M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 9 Nov 2006
- Last trade
- 7 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Bought | $15K10,000 at $1.48 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —16,757 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —7,009 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —4,322 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code D | —2,951 | filing |
| 2 Apr 2025filed 2 Apr 2025 | Intra-Cellular Therapies | SEC FORM 4 Code D | $1.5M11,340 at $132.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 10 Jan 2025filed 14 Jan 2025 | SLS SELLAS Life Sciences GroupBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | Intra-Cellular Therapies | SEC FORM 4 Code A | $5,68583 at $68.49 | filing |
| 23 Jun 2024filed 25 Jun 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —1,567 at $0.00 | filing |
| 23 Jun 2024filed 25 Jun 2024 | Intra-Cellular Therapies | SEC FORM 4 Code M | —1,567 | filing |
| 18 Jun 2024filed 21 Jun 2024 | Intra-Cellular Therapiesoption or derivative | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 18 Jun 2024filed 21 Jun 2024 | Intra-Cellular Therapies | SEC FORM 4 Code M | $337K20,000 at $16.86 | filing |
News
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Here's WhySLS · dailypolitical.com · 20 Oct 2026SELLAS Life Sciences Group (NASDAQ:SLS) Stock Falls 11.2% – Should You Sell?SLS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Robert L. Van Nostrand; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.